The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 557-561

  Charvat, Sandrine ^a   Duchesne, Marc ^b   Parvaz, Parviz ^c   Chignol, Marie Christine ^a   Schmitt, Daniel ^a   Serres, Mireille ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SANOFI   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Farnesyl transferase inhibitor; Ha ras oncogene; Human keratinocytes; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RPR 115135; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CELL MUTANT; CONTROLLED STUDY; DNA TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE H RAS; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR VASCULARIZATION;

ALKYL AND ARYL TRANSFERASES; CELL LINE; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; KERATINOCYTES; LYMPHOKINES; MUTATION; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032928810     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers RH and Folkman J: Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathway. Proc Natl Acad Sci USA 94: 861-866, 1997.
2. Folkman J, Watson K, Ingher D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
3. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24: 203-218, 1997.
4. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature (Lond.) 359: 845-848, 1992.
5. Millauer B, Shawver L, Plate KH, Risau W and Ulrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.) 367: 576-579, 1994.
6. ras in carcinogenesis. Path Res Pract 192: 658-668, 1996.
7. Montano X: In: Keratinocyte Handbook (I. M. Leigh, E. B. Lane and F. Watt, eds). Cambridge, Cambridge University Press, 1994, pp 459-469.
8. Rak J, Mitsuhashi L, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression/ implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
9. Grugel S, Finkenzeller G, Weindel K, Barleon B and Marme D: Both v-Ha-ras and V-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270; 25915, 1995.
10. Larcher F, Robles A, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ and Jorcano JL: Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56: 5391-5396, 1996.
11. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE and Oliff A: Selective inhibition of farnesyl-protein tranferase blocks ras processing in vivo. J Biol Chem 268: 7617-7620, 1993.
12. Leonard DM: ras farnesyltransferase: A new therapeutic target. J Med Chem 40: 2971-2990, 1997.
13. Santillo M, Mondola P, Gioielli A, Serù R, Iossa S, Annella T, Vitale M and Bifulco M: Inhibitors of ras farnesylation revert the increased resistance to oxidative stress in K-ras transformed NIH 3T3 cells. Biochem Biophys Res Commun 229: 739-745, 1996.
14. Boukamp P, Petrasevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771, 1988.
15. Boukamp P, Stanbridge E, Yin Foo D, Cerutti PA and Fusenig NE: C-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 50: 2840-2847, 1990.
16. Bouras M, Parvaz P and Berger N: Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors. Ann Biol Clin 53: 549-555, 1995.
17. Palacio S, Schmitt D and Viac J: Contact allergens and sodium lauryl sulphate upregulate vascular endothelial growth factor in normal keratinocytes. Br J Dermatol 137: 540-544, 1997.
18. Skobe M, Rockwell P, Goldstein N, Vosseler S and Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 3: 1222-1227, 1997.
19. Viac J, Palacio S, Schmitt D and Claudy A: Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 289: 158-163, 1997.
20. Weninger W, Uthman A, Pammer J, Pichler A, Ballaun C, Lang I, Plettenherg A, Bankl HC, Stürzl M and Tschachler: VEGF production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest 75: 647-657, 1997.
21. Tischer E, Mitchell R and Hartman T: The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947-11954, 1991.
22. ras in receptor tyrosine kinase signalling. Biochem Biophys Acta 1198: 131-147, 1994.
23. Vrignaud P, Maillet P, Bissery MC, Duchesne M, Lelièvre Y, Riou JF, Chapelle P, Tocque B and Lavelle F: Structure activity relationship and in vivo evaluation in a new promising family of nonpeptidomimetic farnesyltransferase inhibitors. Proc Am Assoc Cancer Res 38: 350, 1997.
24. Marshall CJ: Reversion and rereversion in ras-transformed cells. Immunol Ser 51: 89-106, 1990.
25. Solanas M and Escrish E: Ha-ras in normal and tumoral tissues: structure, function and regulation. J Physiol Biochem 52: 173-192, 1996.
26. Kikuchi A, Amagai M, Hayakawa K, Ueda M, Hirohashi S, Shimizu N and Nishikawa T: Association of EGF receptor expression with proliferating cells of ras p21 expression with differentiating cells in various skin tumours. Br J Dermatol 123: 49-58, 1990.
27. Zioga C, Malamou-Mitsis VD, Kamina S and Agnantis NJ: Immunohistochemical detection of ras p21 oncoprotein in human skin lesions. Anticancer Res 15: 1015-1022, 1995.
28. Khan SG, Dummer R, Siddiqui J, Bickers DR, Argarwal R and Mukhtar H: Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. Biochem Biophys Res Commun 220: 795-801, 1996.
29. MacNulty EE and Ryder NS: Characterization of prenyl protein transferase enzymes in a human keratinocyte cell line. Biochem Biophys Acta 1289: 41-50, 1996.